Valuation: Norda ASA

Market Cap 51Cr 5.18Cr 4.53Cr 4.19Cr 3.9Cr 7.36Cr 489.83Cr 7.49Cr 50Cr 19Cr 241.71Cr 19Cr 19Cr 842.07Cr P/E 2023 *
-
P/E 2024 3.26x
Enterprise Value 26Cr 2.67Cr 2.34Cr 2.16Cr 2.01Cr 3.79Cr 252.33Cr 3.86Cr 26Cr 10Cr 124.51Cr 10Cr 9.8Cr 433.78Cr EV / Sales 2023
-1.24x
EV / Sales 2024 0.4x
Free-Float
6.26%
Yield 2023 *
-
Yield 2024 32.5%
Manager TitleAgeSince
Chief Executive Officer - 08/04/2013
Director TitleAgeSince
Chairman 54 31/01/2014
Director/Board Member 68 20/06/2013
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+3.37%-6.12% - - 4.47Cr
+1.15%+5.94%-3.40%+2.32% 4.66TCr
-3.03%+10.57%+409.46%+600.67% 4.1TCr
-1.42%+11.82%+21.53%-14.79% 3.23TCr
-1.89%+3.08%+17.59%+59.64% 3.22TCr
-3.29%+2.85%+13.80%+30.30% 2.55TCr
+1.86%+12.60% - - 1.64TCr
-0.56%+12.48%+69.69%+121.76% 1.53TCr
+0.56%+5.09%+13.43%+17.88% 1.36TCr
-0.44%+5.85%+103.58%+96.04% 1.33TCr
Average -0.34%+10.33%+80.71%+114.23% 2.62TCr
Weighted average by Cap. -0.96%+10.36%+94.86%+137.88%

Financials

2023 2024
Net sales 8.69Cr 87.75L 76.81L 70.9L 66.14L 1.25Cr 83Cr 1.27Cr 8.5Cr 3.3Cr 41Cr 3.3Cr 3.22Cr 142.63Cr 37Cr 3.75Cr 3.29Cr 3.03Cr 2.83Cr 5.33Cr 354.94Cr 5.43Cr 36Cr 14Cr 175.15Cr 14Cr 14Cr 610.18Cr
Net income 3.12Cr 31.47L 27.55L 25.43L 23.72L 44.69L 30Cr 45.49L 3.05Cr 1.18Cr 15Cr 1.18Cr 1.16Cr 51Cr 13Cr 1.27Cr 1.11Cr 1.03Cr 95.83L 1.81Cr 120.22Cr 1.84Cr 12Cr 4.78Cr 59Cr 4.78Cr 4.67Cr 206.67Cr
Net Debt -31Cr -3.14Cr -2.75Cr -2.54Cr -2.37Cr -4.46Cr -297.09Cr -4.54Cr -30Cr -12Cr -146.6Cr -12Cr -12Cr -510.72Cr -25Cr -2.51Cr -2.2Cr -2.03Cr -1.89Cr -3.57Cr -237.5Cr -3.63Cr -24Cr -9.45Cr -117.2Cr -9.44Cr -9.23Cr -408.29Cr
Logo Norda ASA
Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Company’s products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.
Employees
-